Debu Tripathy
The University of Texas MD Anderson Cancer Center · 1,183 works · 28,106 citations · h-index 73
Top works
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
- Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
- Circulating Tumor Cells in Patients with Breast Cancer Dormancy
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- HER-2 gene amplification can be acquired as breast cancer progresses
- Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
- Adaptive Randomization of Neratinib in Early Breast Cancer
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
- Image-Detected Breast Cancer: State of the Art Diagnosis and Treatment
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
- Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
- Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment
- First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER